EQT AB is nearing a deal to acquire Qiagen NV for around €9.6 billion ($10.8 billion) bringing an end to years of takeover speculation involving the European molecular testing company, according to people familiar with the matter.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.